作者: D.J. Groves , B.A. Morris
DOI: 10.1089/02724570050109602
关键词:
摘要: The generation of monoclonal antibodies from species other than rats and mice has developed slowly over the last 20 years. advent antibody engineering realization advantages nonmurine antibodies, in terms their superior affinities specificities, potential as components human veterinary therapeutics increased relevance recently. There have been significant advances development myeloma heteromyeloma fusion partners. This is an opportune moment to consolidate experiences MAb production across range interest place it into context with developments field antibodies. background mouse discussed. antigens used date are reviewed, methods results reported. A suggested protocol provided for first attempts exploit huge this aspect hybridoma technology suggestions made its further expansion.